| Q53344748 | 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, The Netherlands. |
| Q34184793 | A humanized Smn gene containing the SMN2 nucleotide alteration in exon 7 mimics SMN2 splicing and the SMA disease phenotype |
| Q38316939 | A mouse model for spinal muscular atrophy |
| Q29617367 | A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy |
| Q26748477 | A structured approach to the assessment of a floppy neonate |
| Q33859087 | Adenoviral cardiotrophin-1 gene transfer protects pmn mice from progressive motor neuronopathy. |
| Q24535295 | An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B |
| Q33760559 | Conserved genes act as modifiers of invertebrate SMN loss of function defects |
| Q36814111 | Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G⁹³A transgenic ALS mice |
| Q64062294 | Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients |
| Q28203025 | Determinants of the interaction of the spinal muscular atrophy disease protein SMN with the dimethylarginine-modified box H/ACA small nucleolar ribonucleoprotein GAR1 |
| Q38704353 | Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy. |
| Q40741164 | Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. |
| Q24200377 | Drug treatment for spinal muscular atrophy type I |
| Q24234523 | Drug treatment for spinal muscular atrophy type I |
| Q24241017 | Drug treatment for spinal muscular atrophy type I |
| Q24244774 | Drug treatment for spinal muscular atrophy type I |
| Q89477851 | Drug treatment for spinal muscular atrophy types II and III |
| Q24200270 | Drug treatment for spinal muscular atrophy types II and III |
| Q24234414 | Drug treatment for spinal muscular atrophy types II and III |
| Q24241759 | Drug treatment for spinal muscular atrophy types II and III |
| Q24244639 | Drug treatment for spinal muscular atrophy types II and III |
| Q24323175 | Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational level |
| Q39549155 | Generation of a tamoxifen inducible SMN mouse for temporal SMN replacement |
| Q38308486 | Genotype determination at the survival motor neuron locus in a normal population and SMA carriers using competitive PCR and primer extension |
| Q28214192 | Increased expression level of the splicing variant of SIP1 in motor neuron diseases |
| Q24613087 | Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism |
| Q28254983 | Induction of full-length survival motor neuron by polyphenol botanical compounds |
| Q34314191 | Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy |
| Q33937593 | Intron 7 conserved sequence elements regulate the splicing of the SMN genes |
| Q34276988 | Mutations in apoptosis genes: a pathogenetic factor for human disease |
| Q28214767 | Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1 |
| Q30483218 | Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy |
| Q28575546 | Neuronal body size correlates with the number of nucleoli and Cajal bodies, and with the organization of the splicing machinery in rat trigeminal ganglion neurons |
| Q47423413 | Newborn genetic screening for spinal muscular atrophy in the UK: The views of the general population |
| Q28261807 | Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts |
| Q33933843 | Nuclear proteins and cell death in inherited neuromuscular disease |
| Q42534833 | P elements inserted in the vicinity of or within the Drosophila snRNP SmD3 gene nested in the first intron of the Ornithine Decarboxylase Antizyme gene affect only the expression of SmD3. |
| Q35692750 | Parents of children with autosomal recessive diseases are not always carriers of the respective mutant alleles |
| Q73694633 | Regions essential for the interaction between Bcl-2 and SMN, the spinal muscular atrophy disease gene product |
| Q34762623 | Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy. |
| Q37409966 | Response and adaptation of skeletal muscle to denervation stress: the role of apoptosis in muscle loss. |
| Q38562045 | Review of Spinal Muscular Atrophy (SMA) for Prenatal and Pediatric Genetic Counselors |
| Q24535039 | SMNrp is an essential pre-mRNA splicing factor required for the formation of the mature spliceosome |
| Q36805205 | Skeletal Muscle in Motor Neuron Diseases: Therapeutic Target and Delivery Route for Potential Treatments |
| Q35796587 | Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches |
| Q33345749 | Spinal muscular atrophy. |
| Q38429727 | Splicing arrays reveal novel RBM10 targets, including SMN2 pre-mRNA. |
| Q35226294 | The floppy infant: contribution of genetic and metabolic disorders |
| Q36301531 | The spinal muscular atrophy disease gene product, SMN: A link between snRNP biogenesis and the Cajal (coiled) body |
| Q73804884 | The survival motor neuron protein of Schizosacharomyces pombe. Conservation of survival motor neuron interaction domains in divergent organisms |
| Q30827153 | Ultrastructural characterisation of a nuclear domain highly enriched in survival of motor neuron (SMN) protein |
| Q35646639 | Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus |